AVR 1.58% $18.70 anteris technologies ltd

Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-2

  1. 842 Posts.
    lightbulb Created with Sketch. 186
    I don't know much abotu this stuff, but my impression is it isn't looking that good. "The study found that there was a statistically significant 52% reduction in viral shedding rate for vaccine recipients, when the post-vaccine period was compared with pre-vaccine, and a non-significant 31% reduction in shedding was observed over the course of the study for the subjects receiving placebo. When the extent of reduction in shedding was compared between the vaccine and the placebo groups, however, the reduction associated with vaccine was non-significant."
    Last edited by Dazaau: 04/05/17
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
(20min delay)
Last
$18.70
Change
-0.300(1.58%)
Mkt cap ! $359.4M
Open High Low Value Volume
$19.00 $19.00 $18.62 $180.3K 9.596K

Buyers (Bids)

No. Vol. Price($)
1 475 $18.70
 

Sellers (Offers)

Price($) Vol. No.
$18.91 100 1
View Market Depth
Last trade - 14.41pm 20/06/2024 (20 minute delay) ?
AVR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.